Lapatinib plus capecitabine for HER2-positive advanced breast cancer: a multicentre study of Anatolian Society of Medical Oncology (ASMO)

• DOI: 10.1179/1973947813y.0000000147
• Publication Date: 2013-11-05T10:22:24Z
• Authors: Bulent Cetin; Mustafa Benekli; Ibrahim Turker; Lokman Koral; Arife Ulas; Faysal Dane; Berna Oksuzoglu; Mehmet Ali Kaplan; Dogan Koca; Cem Boruban; Burcak Yilmaz; Alper Sevinc; Veli Berk; Dogan Uncu; Hakan Harputluoglu; Ugur Coskun; Suleyman Buyukberber
• Keywords: Lapatinib

Lapatinib is the first dual tyrosine kinase inhibitor of human epidermal growth factor receptor type 2 (HER2/neu) and (EGFR). The present study evaluated efficacy tolerability combination lapatinib capecitabine in patients with metastatic breast cancer (MBC) who progressed after therapy trastuzumab, a taxane and/or anthracycline. A total 203 median age 48 years (range: 25-82 years) were retrospectively 11 centres between September 2007 May 2011. All had HER2-positive MBC progressing trastuzumab chemotherapy including an anthracycline taxane. treated (1250 mg/day, continuously) (2000 mg/m(2) on days 1 through 14 21-day cycle). Data demographics, clinical outcome, toxicity collected for descriptive analyses. follow-up was 10·7 months 1-40 months). An overall response rate (ORR) 33·4% achieved 7 complete responses (CR, 3·4%), 61 partial (PR, 30·0%), 44 stable disease (37·9%). Clinical benefit 71·3% achieved. Median progression-free survival (PFS) (95% CI: 6-10 months), (OS) 15 12-18 most common side effects hand-foot syndrome (46·8%), nausea (42·3%), fatigue (42·2%), anorexia (38·5%), diarrhea (31·5%), rash (29·6%). Grade 3-4 toxicities identified as hand foot (7·9%), (6·9%), (5·9%), (5·4%). There no symptomatic cardiac events. effective well tolerated progressive taxane, therapy, evidenced by this retrospective evaluation. Toxicity mild to moderate low grade toxicity.